⭐ Featured Analysis
STAREE: Atorvastatin Cuts Cardiovascular Events but Not Disability in Elders
Can atorvastatin extend disability-free life in seniors without heart disease?
Read Full Analysis →Newest Analyses
Palliative CarePharmacist Telemedicine Partially Offset Palliative Access Loss During Oncology Clinic Staffing Shortage
Infectious Disease / AntimicrobialsPharmacist Prescribing for ED Culture Callbacks: 11-Month CPA Implementation Report
Infectious Disease / AntimicrobialsDe-escalation in Severe Abdominal Sepsis: Association With Cure, Not Proof of Benefit
Geriatrics / Geriatric PharmacyMedication Optimisation in Older Adults: From Structured Review to Accountable AI
★ Editor's Picks
One in Four Carboplatin Shortage Allocations Missed Policy Intent★ Must ReadOncology Pharmacy
Chemotherapy-Free Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Adult Ph-Positive ALLOncology Pharmacy
Milvexian Fails to Reduce Ischemic Events After ACSAnticoagulation / Hematology
Polish Psychiatric Association Guides Metabolic Risk Management in Antipsychotic UsersPsychiatry / Psychopharmacology
💊 Clinical Pearl of the Week
De-escalation in Severe Abdominal Sepsis: Association With Cure, Not Proof of Benefit Infectious Disease / Antimicrobials
Expect weaker support in MDRO infection (OR 1.37, 95% CI 0.48–3.90), so individualize decisions and involve infectious diseases input.
⚡ Practice-changing
- Chemotherapy-Free Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Adult Ph-Positive ALL
- BSR 2026 Polymyalgia Rheumatica Guideline: Bone Protection, Faster Tapers, Early Methotrexate, IL-6R Blockade
- Polish Psychiatric Association Guides Metabolic Risk Management in Antipsychotic Users
- STAREE: Atorvastatin Cuts Cardiovascular Events but Not Disability in Elders
Most-read this week
1Chemotherapy-Free Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Adult Ph-Positive ALLOncology Pharmacy
3Polish Psychiatric Association Guides Metabolic Risk Management in Antipsychotic UsersPsychiatry / Psychopharmacology